CD8A and neoplasm: Though AB680@EMVs-aPD-L1 didn’t show a significantly better tumor inhibition effect than free AB680 + aPD-L1, it had a longer median survival (Fig. 3c) and CD8+/CD4+ ratio in tumor tissues (Fig. 3d).